Could a simple gel stop UTIs from coming back?
NCT ID NCT07233473
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a vaginal gel called Multi-Gyn UT Protect to see if it can prevent repeated urinary tract infections (UTIs) in women. Fifty adult women who have had multiple UTIs in the past year but no current infection will apply the gel twice a week for four months. Researchers will track how many women remain UTI-free during that time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Multi-Gyn UT Protect gel (vaginal gel)
- What this could lead to
- If it works, this gel could offer a non-antibiotic way to prevent frequent UTIs, reducing the need for repeated antibiotic courses.
- What could go wrong
- This is a small, early-stage trial with only 50 participants and no placebo group, so results may not be definitive. The gel may not prevent UTIs for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 84 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age: 18 to 84 years old. 2. Sex: Female. 3. Subject suffering from uncomplicated recurrent urinary tract infections: ≥ 4. UTIs within 12 months or ≥ 2 within 6 months. 4. Subject having given freely and expressly her informed consent. 5. Subject using a contraceptive regimen recognized as effective (pill, implant, Intra Uterine Device (IUD), condoms) since at least 12 weeks before inclusion visit and during the whole study. If subject use condoms as contraceptive regimen, a delay of 6 hours between application and sexual intercourse must be respected. 6. Subject affiliated to a health social security system. 7. Subject cooperative and aware of the device's modalities of use and the necessity and duration of the follow-up visits so that perfect adhesion to the protocol can be expected. Exclusion Criteria: 1. Pregnant or nursing woman or planning a pregnancy during the study. 2. Subject who gave birth in the 3 previous months. 3. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship. 4. Subject in a social or sanitary establishment. 5. Subject suspected to be non-compliant according to the investigator's judgment. 6. Subject having received 6000 euros indemnities for participation in clinical research in the 12 previous months, including participation in the present study. 7. Subject enrolled in another clinical trial or which exclusion period is not over. 8. Subject with history of complicated urinary tract infection. 9. Subject with urinary tract infection at the time of inclusion. 10. Subject with vaginal mycosis infection in the last 3 weeks. 11. Subject with recurrent vaginal mycosis (more than 2 in the last 6 months). 12. Subject having a known allergy or hypersensitivity to one of the components of the investigational device. 13. Subject suffering from a sexually transmitted gynaecological infection or aerobic vaginitis (including gonorrhoea, chlamydia trachomatis or mycoplasma genitalium infection with cervicitis, urethritis, salpingitis). 14. Subject with history of hormone-dependent cancer or bladder cancer. 15. Subject with current genital malignancies. 16. Subject who had a chemotherapy treatment for a cancer in the 12 months before inclusion. 17. Subject who had a radiotherapy treatment in the genito-urinary area in the 12 months before inclusion. 18. Subject using treatment for urinary tract infection, vaginal conditions, vaginal infections, or other intravaginal treatment at the time of inclusion. 19. Subject using food supplements for prevention of urinary tract infection in the last 3 months. 20. Subject using antibiotics, corticoids or antifungal treatment for any reason in the 3 weeks before inclusion. 21. Subject using vaginal douches and who do not wish to refrain using them during the clinical investigation. 22. Subject with a pessary. 23. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Recurrent uncomplicated urinary tract infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Eurofins Dermscan Pharmascan
RECRUITINGVilleurbanne, 69100, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Texting away UTIs: could a phone platform cut unnecessary antibiotics?
- New symptom diaries aim to improve daily tracking of recurrent UTIs, especially for seniors
- Could fewer antibiotics be better for older women with urinary symptoms?
- Could a probiotic plus smart antibiotic use end the cycle of recurrent UTIs in children?
- UTI superbugs: study reveals resistance patterns in uganda
- Scientists create first tools to measure recurrent UTI burden